Daniel M. Girardi

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Andrea B. Apolo, Rosa Nadal, Daniel M. Girardi et al. · Journal of Clinical Oncology · 2020 · 137 citations · Full text

Medicine, Oncology, Pharmacology +12

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Gustavo dos Santos Fernandes, Daniel M. Girardi, João Paulo Giacomini Bernardes et al. · BMC Cancer · 2018 · 82 citations · Full text

Veterinary Medicine, Oncology, Surgery +14

Drug interactions in cancer patients: A hidden risk?

Rachel P. Riechelmann, Daniel M. Girardi · Journal of Research in Pharmacy Practice · 2016 · 26 citations · Full text

Medicine, Oncology, Pharmacology +16

Molecular Profiling of Exceptional Responders to Cancer Therapy

Marijo Bilušić, Daniel M. Girardi, Yan Zhou et al. · The Oncologist · 2020 · 24 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors

Andrea B. Apolo, Daniel M. Girardi, Scot A. Niglio et al. · Journal of Clinical Oncology · 2024 · 24 citations · Full text

Medicine, Oncology, Pharmacology +15